Aspire Biopharma Holdings (ASBP) Total Non-Current Liabilities (2022 - 2025)
Aspire Biopharma Holdings (ASBP) posted quarterly Total Non-Current Liabilities of $7.6 million for Q4 2025, up 543.26% year-over-year from $1.2 million in Q4 2024, and down 10.88% quarter-over-quarter from $8.6 million in Q2 2025.
Aspire Biopharma Holdings (ASBP) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Total Non-Current Liabilities for 4 consecutive years, with $7.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 543.26% year-over-year to $7.6 million; the TTM figure through Dec 2025 stood at $7.6 million (up 543.26% YoY), while the FY2025 annual figure was $7.6 million, up 543.26% from the prior year.
- Total Non-Current Liabilities declined to $7.6 million in Q4 2025 per ASBP's latest filing, from $8.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $11.1 million in Q4 2022 and bottomed at -$449214.0 in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $4.5 million across 4 years, with a median of $4.0 million in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 242.01% — and 2025, when it surged 543.26%.
- Aspire Biopharma Holdings' Total Non-Current Liabilities stood at $11.1 million in 2022, then plunged by 97.77% to $247480.0 in 2023, then jumped by 380.39% to $1.2 million in 2024, then soared by 543.26% to $7.6 million in 2025.
- Business Quant data shows ASBP's Total Non-Current Liabilities at $7.6 million in Q4 2025, $8.6 million in Q2 2025, and $8.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.65 Mn |
| Jun 30, 2025 | 8.58 Mn |
| Mar 31, 2025 | 8.04 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | -449,214.00 |
| Jun 30, 2024 | 5.79 Mn |
| Mar 31, 2024 | 2.18 Mn |
| Dec 31, 2023 | 247,480.00 |
| Sep 30, 2023 | 316,316.00 |
| Dec 31, 2022 | 11.12 Mn |